Choices About Genetic Testing And Learning Your Risk With Smart Technology
Completed · Not applicable
Conditions studied: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
In brief
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors. The study will focus on the feasibility and acceptability of a digital intervention designed to improve cancer genomic care. The study objectives are to: 1. Finalize the development and optimize the usability of the CATALYST digital intervention (also known as the relational assistant \[RA\]). 2. Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model for cancer survivors. Participants will be randomized to one of two study arms: the RA intervention arm or the enhanced usual care (EUC) arm. 3. Assess the uptake of genetic counseling (GC) and genetic testing (GT) and conduct a process evaluation to identify barriers and facilitators to GC, GT, and engagement with the CATALYST intervention and the RA.
Key facts
- Study ID
- NCT06184867
- Run by
- Rutgers, The State University of New Jersey
- People needed
- 50
- Starts
- 2023-09-26
- Expected to finish
- 2025-06-26
- Last updated by the study team
- 2026-03-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- User/Usability Testing
- Age 18 or older
- Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer
- Speak/read and understand English
- Capable of providing informed consent
- Have Internet access (via smartphone, tablet, or computer)
- Randomized Feasibility Trial
- Age 18 or older
- Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer
- Meet National Comprehensive Cancer Network (NCCN) criteria for germline GT
- Speak/read and understand English
- Capable of providing informed consent
- Have Internet access (via smartphone, tablet or computer)
You may not qualify if…
- Participants will be 18 years of age or older because germline genetic testing is generally not recommended in children when the test results would not impact clinical management. Participants from the user and usability testing phases are not eligible for the feasibility trial. Feasibility trial participants cannot have previously undergone germline GT for hereditary cancer risk.
Where it is running
- Rutgers University — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.